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Abstract Current imaging methods have focused on evalu-
ation of myocardial anatomy and function. However, since
myocardial metabolism and function are interrelated, meta-
bolic myocardial imaging techniques, such as positron
emission tomography, single photon emission tomography,
and magnetic resonance spectroscopy present novel opportu-
nities for probing myocardial pathology and developing new
therapeutic approaches. Potential clinical applications of
metabolic imaging include hypertensive and ischemic heart
disease,heartfailure,cardiactransplantation,aswellascardio-
myopathies. Furthermore,response to therapeuticintervention
can be monitored using metabolic imaging. Analysis of
metabolic data in the past has been limited, focusing primarily
on isolated metabolites. Models of myocardial metabolism,
however, such as the oxygen transport and cellular energetics
model and constraint-based metabolic network modeling,
offer opportunities for evaluation interactions between greater
numbers ofmetabolites in the heart. Inthis review, the rolesof
metabolic myocardial imaging and analysis of metabolic data
using modeling methods for expanding our understanding of





Cardiac imaging plays an integral role in the diagnosis and
management of heart disease. Coronary angiography,
echocardiography, and single photon emission tomography
(SPECT) are well established clinically, with defined
indications and benefits. Newer imaging tools, including
cardiac computed tomography (CT), magnetic resonance
imaging (MRI), magnetic resonance spectroscopy (MRS),
and positron emission tomography (PET) are increasing in
importance and proving themselves to be valuable tools in
disease management. Guidelines are now in place, for
instance, for the application of cardiac CT in coronary artery
disease [1]. MRI is currently being used in the evaluation of
congenital heart disease, cardiac tumors, right ventricular
dysplasia, and pericardial disease. Other uses for MRI,
including measurement of myocardial perfusion and left
ventricular function are being studied and show promise.
Although of great clinical benefit from an anatomical
perspective, coronary angiography, echocardiography, and
cardiac CT do not deliver information regarding patient
specific, clinically relevant metabolic processes. The appli-
cation of hybrid technology, combining CT with metabolic
PET and SPECT are currently under evaluation. Data
obtained from quantitative metabolic imaging modalities
such as PET add functional information to the anatomic
imaging modalities and can aid with patient management.
An area of particular interest is the management of
congestive heart failure (CHF), a disease process which leads
to specific changes in cardiac function and metabolism. CHF
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increasing in prevalence. Despite advances in medical
management, optimal treatment remains challenging.Applied
metabolic imaging in heart failure patients may potentially
contribute to improved treatment outcomes. Current research
initiativesincludeevaluationoflocalmyocardialconditionsin
ischemic cardiomyopathy associated with arrhythmogenesis
and potential identification of responders to cardiac resyn-
chronization therapy (CRT) [2]. Pre-procedure use of phase
analysis has been able to identify responders by measuring
LV dyssynchrony using conventional electrocardiogram-
gated SPECT myocardial perfusion imaging, requiring no
additional procedures [3]. This method shows promise as it
appears to demonstrate both repeatability and reproducibility.
Evaluation of metabolic parameters as markers of viability
may also be linked to CRT response and deserves further
attention [4]. Furthermore, quantitative metabolic imaging
may play a role in tailoring medical management with
metabolic modulators such as trimetazidine, which have
recently generated interest in heart failure management
[5, 6]. Application of such metabolic agents may allow for
optimization of myocardial energy production. The effects
on myocardial perfusion, free fatty acid, and oxidative
metabolism can be directly assessed using PET imaging,
thus potentially contributing to new pharmacologic therapy
options in heart failure patients.
An eminent biochemical engineer Jay Bailey once enu-
merated several reasons for mathematical model construction
as a worthwhile scientific endeavor, which included: organiz-
ing disparate information into a coherent whole to discover
newstrategies,tounderstandtheessential/qualitativefeatures,
to think (and calculate) logically what components and
interactions are important in a complex system, and to make
important corrections to conventional wisdom [7]. These
points become immediately clear when one considers the
requirements to develop translational pipelines from the
basic science bench to the hospital bedside. There has been a
long and accomplished history of constructing models of
various aspects of cardiac function from electrophysiology to
metabolism during the past century. Here we briefly touch
upon mathematical models on myocardial cellular energetics
and metabolism and discuss potential applications of these
models in the analysis of metabolic data obtained with PET,
MRS, and SPECT myocardial imaging technologies as well
as the Fick method and high-throughput metabolic profiling.
Overview of Myocardial Metabolism
Contractile shortening as well as maintenance of cellular
energetics and the sarcoplasmic reticulum calcium pump of
cardiomyocytes are fueled by oxidation of fatty acids and
carbohydrate substrates. During contraction, regulation of
substrate supply begins with an increase in the workload,
which is governed by the Frank-Starling law under normal
physiological conditions. Aworkload-dependent increase in
the rate of the actomyosin ATPase results in the release of
adenosine diphosphate (ADP) and phosphate and the signal
is transmitted via the mitochondrial adenine nucleotide
translocase, ultimately resulting in the activation of aden-
osine triphosphate (ATP) synthase and the utilization of the
proton transmembrane electrochemical gradient [8]. This
process leads to an increase in electron transfer to oxygen
through the respiratory chain and NADH and FADH2
oxidation. Thus, increased workload decreases the NADH:
NAD + ratio in the mitochondrial matrix, resulting in an
increase in the rates of the dehydrogenase reactions in the
citric acid cycle. NADH and FADH2 are produced in the
citric acid cycle as well as in the fatty acid beta oxidation
pathway, and to a lesser extent from glycolysis and the
pyruvate dehydrogenase reaction [9].
The rates of oxygen consumption and free fatty acid
oxidation increase linearly with elevation of the workload. If
workload increases, ATP production and respiration are
increased due to feedback signaling via the creatinine kinase
system. Activation of the Krebs cycle results in a decrease in
acetyl-CoA in the mitochondrial matrix. In the cytoplasm
acetyl-CoA is converted by acetyl-CoA carboxylase (ACC)
tomalonyl-CoA,whichisan inhibitorofcarnitine palmitoyl-
transferase I (CPT I) and thus the transfer of acyl groups into
mitochondria for beta oxidation. ACC is inhibited upon its
phosphorylation by adenosine monophosphate activated
protein kinase (AMPK), and this reaction sequence serves
as the basis for the hypothesis advocated in recent works,
according to which malonyl-CoA is a key regulator of fatty
acid oxidation [8]. However, as an alternative, malonyl-
CoA could be considered as an inhibitory signal, while a
key regulator of respiration rate and fatty acid oxidation
may be the actual energy demand and workload [8]. Thus,
decrease in malonyl-CoA may not be the reason but rather
the consequence of the increases in workload and fatty acid
oxidation. Malonyl-CoA seems to be at the end of this
sequence of events, and the AMPK signaling pathway
apparently modifies only this last step of regulation under
cellular stress conditions where AMP/ATP ratio increases
significantly [8].
In the presence of both carbohydrate substrates and free
fatty acids, approximately 60% to 90% of oxygen consumed
is used for oxidation of free fatty acids. According to the
Randle hypothesis, if glucose and free fatty acids are both
present, free fatty acids inhibit transport of glucose across the
plasma membrane and slow down oxidation of glucose and
pyruvate. Furthermore, aerobic glycolysis is limited by the
necessity to maintain a low NADH/NAD+ ratio in the cyto-
plasm necessary for a high steady-state flux through the
glyceraldehyde 3-phosphate dehydrogenase that is accom-
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drial matrix by the malate-aspartate shuttle [8]. The shuttle
becomes the rate limiting step at medium workloads, while
the fatty acid pathway does not have this type of limitation.
Nevertheless, flexibility of myocardial substrate metabolism
appears to be important for cardiac health. Loss of this
metabolic plasticity with overdependence of metabolism on
an individual substrate can be seen in pathologic conditions
with predominance in fatty acid metabolism in diabetic heart
disease and accelerated glucose use associated with pressure
overload left ventricular hypertrophy [9], which we wish to
evaluate with imaging methods.
Since the myocardium’s preference for a given fuel
substrate can be manipulated, quantitative evaluation of
myocardial metabolism can be particularly challenging. For
example, after 5–24 h of fasting, when circulating free fatty
acids became high and insulin concentrations became low,
myocardial glucose utilization rates in normal volunteers
averaged only 0.24±0.17 umol/min gm while ingestion of
carbohydrates with stimulation of insulin secretion raised
glucose utilization to 0.69±0.11 umol/min gm [10]. There-
fore, investigators should attempt to standardize the meta-
bolic environment, requiring a steady-state condition for
quantitative analysis of myocardial metabolism. In this
respect, either the fasting state or the euglycemic hyper-
insulinemic clamp, which produce stable insulin and glucose
concentrations in plasma, are suitable for maintaining a
metabolic steady-state [11] .T h eo r a lg l u c o s e - l o a d e ds t a t e ,o n
the other hand, results in a gradual change in plasma-glucose
and insulin levels, which alter the metabolic rate of glucose
in the myocardium. The euglycemic hyperinsulinemic clamp
technique requires a steady IV infusion of insulin to be
administered in one arm. The serum glucose level is
“clamped” at a normal fasting concentration by administering
avariableIVglucoseinfusionintheotherarm[12]. However,
the clamp technique is a rather cumbersome procedure,
requiring frequent measurements of plasma-glucose and
insulin levels. The fasting state, on the other hand, seems
to be a simple and reliable choice for keeping metabolism in
a stable condition. Therefore, when myocardial models are
applied to the metabolic data, investigators should acknowl-
edge the metabolic environment in which the data was
obtained and whether the study subject is glucose intolerant
to ensure that comparisons between data sets are made under
equivalent metabolic conditions.
In Vivo Quantification of Myocardial Metabolism
Positron Emission Tomography
PET has been utilized in clinical practice for assessment of
myocardial perfusion and metabolism, using predominantly
qualitative (Fig. 1) or semiquantitative approaches. How-
ever, PET can also be used to assess tissue metabolism
quantitatively. PET measures spatiotemporal concentrations
of radiopharmaceuticals, such as radiolabeled glucose or
fatty acids, in organs in absolute units [13]. These measure-
ments can be performed noninvasively in human subjects or
in animals such as rats, monkeys, or knockout mice. The
resolution of PET scanners can be as low as 3 mm for
human imaging and 1.3 mm for imaging small animals
using a microPET camera. Positron emitting radioisotopes
are composed of unstable parent nuclei which contain a
greater number of high-energy protons than the number of
neutrons. An unstable proton decays to a neutron in the
nucleus, and a positron and a neutrino are emitted. The
positron typically travels a distance of several millimeters
or more, losing some of its energy, until it undergoes
annihilation with an electron, resulting in the production of
two anti-parallel 511-keV photons. These photons can be
detected with a PET camera, which contains high-density
crystal detectors and coincidence circuitry, and the data is
reconstructed to create tomographic images [14].
Fig. 1 13N-ammonia axial PET myocardial perfusion images (column
A) and 18F-FDG axial PET myocardial metabolism images (column B)
in a 49-year-old male history of cardiomyopathy. Images demonstrate a
mismatched pattern of decreased myocardial perfusion with preserved
18F-FDG metabolism (small arrows) in the inferoseptal and inferior
walls, suggesting the presence of viable hibernating myocardium.
Furthermore, there is a matched pattern of decreased myocardial
perfusion and metabolism (large arrow) in the proximal to mid
inferolateral wall, which is compatible with an infarct
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isotopes such as 15O, 13N, 11C, and 18F, which are
generated in the cyclotron, can be directly substituted for
oxygen, nitrogen, carbon, and hydrogen atoms in biological
molecules. These PET radiopharmaceuticals, when injected
into human subjects or animals at tracer concentrations, can
be used to monitor biological processes without altering
these processes. The sensitivity of PET for detection of
radiotracers is very high, in the picomolar to femtomolar
range. Aradiotracermust be relatedto the processof concern
and it is preferred that no labeled metabolites of the
radiotracer accumulate in the tissue of interest. In general,
the amount of the tracer should be at least several orders of
magnitude smaller than that of the traced molecule. PET
radiopharmaceuticals that have been useful in the evaluation
of myocardial metabolism are listed in Table 1. Radiotracers
can consist of radiolabeled natural substrates or chemical
analogs. The advantage of using radiolabeled chemical
analogs such as 18F-fluorodeoxyglucose (18F-FDG) as
radiotracers is that they can be used to isolate selected
portions of complex biochemical reaction sequences, such
as the facilitated transport across cell membrane [14]. The
advantage, on the other hand, of using a natural substrate
such as glucose to create the radiotracer 11C-glucose is that
there is no need for correction terms for different affinities
of transporters and enzymes. However, 11C-glucose goes
through many reaction steps in the glycolytic pathway
before it is cleaved away as 11C-CO2 and soon found in
other labeled compounds, making it a challenge to use this
radiotracer to isolate a specific reaction sequence.
Quantitative biological reaction flux parameters, such as
the metabolic rate of glucose, can be obtained with PET by
performing (1) dynamic PET imaging, (2) arterial blood
sampling, and (3) employing a kinetic model for a given
radiopharmaceutical. First, however, a three-dimensional
image of a phantom of known specific activity, containing
radiotracer diluted in saline, is acquired to obtain a
conversion factor, which is later used to convert activity
data from tomographic images to absolute concentration
units. Subsequently, the radiopharmaceutical of known
specific activity is injected intravenously or inhaled as a
bolus. Next, dynamic PET imaging is performed, which
consists of an acquisition of many sequential data sets that
are later used to generate tissue–time–activity curve (TAC)
for a given volume of organ tissue outlined by a region of
interest on the images. While dynamic images are being
acquired, many sequential arterial blood samples are
collected, which are later used to generate a plasma–time–
activity curve. Finally, a kinetic compartment model or
graphical analysis of data is used to obtain quantitative
biological parameters such as flux levels of reactions. The
plasma–time–activity curve serves as an input function for
the kinetic compartment model, while the TAC serves as
the output function [14]. Since arterial blood sampling is an
invasive procedure, the input function may sometimes be
approximated using data obtained through sampling of the
mixed-venous blood or dynamic imaging of the radiotracer
within the left ventricle. An ideal plasma–time–activity
curve would only be composed of data from the authentic
tracer;however,itistypicallycontaminatedtovariousdegrees
with data from metabolized tracer. The degree of contamina-
tion is typically evaluated using HPLC column. Furthermore,
it is important to identify the amount of radiotracer that
persists in the plasma and the amount that is taken up by the
red blood cells following intravenous or oral administration,
in order to obtain an accurate input function.
Quantitative biologic parameters such as metabolic
reaction rates can be obtained from PET data and arterial
sampling data using (A) model driven methods or (B) data-
driven methods. Model driven methods use compartments
to describe the behavior of the tracer and to obtain micro
system parameters, such as rate constants. Examples of
biologic compartments include the plasma compartment,
interstitial space and the intracellular compartment (Fig. 2).
A compartment model can be reasonably analyzed with
standard mathematical methods if a first-order process is
assumed, where rate constants are independent of concen-
trations and time [14]. Processes involving PET imaging
are typically pseudo first-order, since the concentration of
one reactant, the radiotracer, is very small compared to the
others, and equations simplify to the same form as for a
first-order process. This modeling approach also assumes
that the dynamic biological process is evaluated in a steady
state, meaning that the rate of a process is not changing
with time and the amount of traced molecule is constant
during evaluation period. The radiotracer is considered to
be distributed uniformly within a compartment and separate
compartments can be combined to form a single compart-
ment if the transport rates between them are not limiting. A
compartment model is described in terms of linear first-
order ordinary differential equations (Fig. 2). Compartment
Table 1 PET radiopharmaceuticals utilized in quantitative myocardial
imaging, their physical half lives, and the biological parameters which
the radiopharmaceuticals can be used to measure in heart tissue
Radiopharmaceutical Half life (min) Parameter
11C-acetate 20 Oxygen flux
11C-glucose 20 Glucose flux
18F-FDG 110 Glucose flux
11C-palmitate 20 FFA flux
18F-FTHA 110 FFA flux
11C-lactate 20 Lactate flux
15O-water 2 Blood flow
13N-ammonia 10 Blood flow
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obtained by fitting the compartment models to measured
data [14].
Data-driven methods, on the other hand, such as
graphical analysis or spectral analysis derive a macro
system parameter, such as the influx rate constant Ki,
which is a composite of the k1, k2, and k3 rate constants,
from a less constrained description of the kinetic processes.
The actual influx rate of a substrate can be obtained by
multiplying the influx rate constant by the arterial concen-
tration of the substrate. Data-driven methods require no a
priori decision about the most appropriate model structure.
The graphical methods, such as the Patlak plot for irreversible
uptake(Fig.3), employ a transformation of the data such that
the linear regression of the transformed data yields to macro
system parameter interest [14]. These methods are attractive
and elegant due to their simplicity. However, they require the
determination of when the plot becomes linear, which may
be biased by statistical noise, and they do not return
information about compartmental structure.
One of the disadvantages of PET is that all radioisotopes
decay with photons having the same energy of 511 keV.
Therefore, it is not possible to image several radiotracers
simultaneously at different energy windows in order to
evaluate myocardial metabolism of several different sub-
strates. Instead, it is necessary to evaluate the metabolism of
each substrate separately by performing sequential studies on
a given subject. Once a subject has been injected with the first
radiopharmaceutical, it is necessary to wait for that radio-
pharmaceutical to decay before another radiotracer can be
injected. Therefore, it is advantageous for the radioisotopes to
have short half lives for sequential metabolic myocardial PET
imaging. An imaging protocol has been developed which
takes advantage of the short half lives of the 15O and 11C
radioisotopes to sequentially obtain quantitative measure-
ments of myocardial blood flow (MBF) with 15O-water
(imaging time of 5 min); myocardial oxygen consumption
(MVO(2)) with 11C-acetate (30 min); myocardial glucose
uptakeandutilization(MGU)with11C-glucose(60min);and
myocardial fatty acid uptake, utilization (MFAU), and
oxidation (MFAO) with 11C-palmitate (30 min) in human
subjects [15]. This protocol has been applied by Dávila-
Román et al. [15], for instance, to quantitatively evaluate
myocardial metabolism in patients with idiopathic dilated
cardiomyopathy (IDCM). In this study, seven patients with
IDCM and normal controls underwent positron emission
tomography for measurements of MBF, MVO(2), MGU,
MFAU, and MFAO. Dávila-Román et al. [15]d e m o n s t r a t e d
that patients with IDCM exhibit alterations in myocardial
metabolism characterized by decreased fatty acid metabolism
and increased myocardial glucose metabolism, a pattern
Fig. 3 Dynamic image set of
the myocardium obtained with
18F-FDG PET and the plasma–
time–activity curve Cp(t) are
used to generate a parametric
horizontal long axis image of
the heart, where the value of
each pixel represents the mag-
nitude of the influx contestant
Ki. Pixel by pixel processing
was performed using the Patlak
graphical analysis
Fig. 2 Two tissue compartment model described in terms of
differential equations. C0 represents radiotracer concentration in the
blood pool compartment, C1 in interstitial space, and C2 in the
intracellular compartment. K1, k2, k3, and k4 represent intercompart-
mental rate constants
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[16] also utilized this serial quantitative myocardial imaging
protocol to study the effect of endurance exercise training
(EET) on myocardial substrate metabolism in older men and
women. The authors found that EET in older individuals
improves the catecholamine response of myocardial glucose
metabolism.
Although this serial imaging protocol enables quantifica-
tion of myocardial metabolism of several important sub-
strates, it does not evaluate the metabolism of lactate, another
important substrate for the heart. Noninvasive quantitative
measurements of myocardial lactate metabolism have been
difficulttoperforminhumans.Herreroetal.performedapilot
study on dogs, showing that under conditions of net lactate
extraction, L-3-(11)C-lactate faithfully traces myocardial
metabolism of exogenous lactate and that measurements of
lactate metabolism are feasible with PET using myocardial
clearance analysis (oxidation) or compartmental modeling
[17]. A large body of evidence has demonstrated that an
uncoupling of glycolysis from glucose oxidation resulting in
myocardial acidosis can contribute to a number of cardiac
pathologies. Another limitation of PET has been the inability
to directly separate out rates of glycolysis from glucose
oxidation with currently available tracers, although recently
it has been demonstrated that PET with 11C-glucose can be
utilized to estimate rates of glycogen synthesis, glycolysis,
and glucose oxidation [18].
Although radioisotopes with short half lives allow for
sequential quantitative metabolic myocardial PET imaging
of several different substrates, the short half lives prevent
these tracers from being used in clinical practice at sites
where a cyclotron is not available. For this reason, radio-
tracers with longer half lives have been implemented, such
as 18F-fluorodeoxyglucose to analyze myocardial glucose
metabolism and 18F-fluoro-6-thia-heptadecanoic acid (18F-
FTHA) to assess myocardial fatty acid metabolism. Taylor
et al. [19], for instance, conducted an evaluation of
myocardial fatty acid and glucose uptake using PET with
18F-FTHA and 18F-FDG in patients with congestive heart
failure. From the dynamic image data, the fractional uptake
rates (Ki) were determined for 18F-FTHA and 18F-FDG.
Subsequently, serum free fatty acid and glucose concen-
trations were used to calculate the myocardial free fatty acid
and glucose uptake rates. In contrast to results obtained by
Dávila-Román et al. for patients with IDCM, Taylor et al.
found that myocardial fatty acid uptake rates in heart failure
are higher than expected for the normal heart, whereas
myocardial glucose uptake rates are lower. This shift in
myocardial substrate use may be an indication of impaired
energy efficiency in the failing heart, providing a target for
therapies directed at improving myocardial energy efficiency.
Furthermore, the authors demonstrated that myocardial free
fatty acid and glucose use in heart failure can be quantita-
tively assessed using PET with 18F-FTHA and 18F-FDG.
However, since 18F-FDG is a chemical analog it may not be
as accurate at evaluating the metabolism of the traced
molecule glucose as the radiolabeled natural substrate 11C-
glucose. Indeed, Herrero et al. [20] have demonstrated that
over a wide range of conditions, PET-derived measurements
of glucose uptake rate are obtained more accurately with
11C-glucose than with 18F-FDG.
Magnetic Resonance Spectroscopy
While MRI provides information on the spatial location and
local chemical environment of protons, MRS provides a
biochemical analysis of the myocardial tissue, making it akin
to a virtual biopsy of the heart. The basis for nuclear
magnetic resonance (NMR) is the quantum interaction
between a nuclear spin of nuclei such as 1H, 31P, 23Na,
and 13C,andan external magnetic field. These nuclei release
a frequency signal in the range of normal radio waves when
perturbed by a radiofrequency pulse [21]. The strength of
the signal depends on the strength of the external magnetic
field. The greater the field strength, the stronger is the
observed signal and the better the signal to noise ratio of the
observed spectrum. (31)P-MRS allows for the detection of
adenosine triphosphate, phosphocreatine (PCr), inorganic
phosphate (Pi), and intracellular pH. In addition to the
measurement of 31P metabolites, MRS 1H, and 13 C MRS
have also been utilized in animal studies [22, 23].
Szczepaniak et al. [22] demonstrated for the noninvasive
in vivo 1H-MRS measurement of intracellular TG is
feasible within myocytes at 1.5-T field strengths and is
comparable in accuracy to biochemical measurement. The
additional application of 1H-MRS has allowed for the
detection of total creatine, enabling an in depth examination
of the creatine kinase system [24]. All these compounds are
involved in the regulation of the available energy from ATP
hydrolysis via the creatine kinase (CK) reaction [25]. PCr
forms the primary ATP buffer in the cell via the CK reaction
and is involved in transporting the chemical energy from the
ATP-producing mitochondria to the ATP-consuming con-
tractile proteins [24].
The MR signal of 31P tends to be relatively weak,
similar to that of 1H-MRS for compounds other than water
and lipids containing 1H. The low signal of 31P can be
partially compensated by using techniques such as nuclear
overhauser enhancement, which increase the signal of 31P
by pre-excitation of the adjacent protons. The “scarcity” of
the MR signal of 31P limits spatial resolution. Several
different techniques can be used to obtain MRS spectral
data, including point-resolved spectroscopy and stimulated
echo acquisition mode, which are more typically applied
with 1H-MRS, and depth-resolved spectroscopy. Image-
selected in vivo spectroscopy demonstrates high spatial
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to motion artifacts and cardiac gating. Chemical-shift
imaging is capable of obtaining multiple spectra relative
to the voxels of a single slice (two dimensional) or several
slices (three dimensional) [25].
MRS can provide metabolic insights into the role of
cardiac metabolism, in particular, cardiac energetics, in
various conditions, including hypertensive, valvular, and
ischemic heart disease; heart failure; cardiac transplanta-
tion; and cardiomyopathies [26]. Furthermore, response to
therapeutic intervention can be monitored using this
method. To study the metabolic changes that occur in heart
failure, (31)P- and (1)H-MRS have been applied in both
patients and experimental animal studies. MRS examination
of the heart failure has revealed that the PCr/CK system is
impaired. PCr levels as well as total creatine levels are
reduced in patients and experimental models and in severe
heart failure ATP is also reduced. These findings have led
to the concept that the heart is energy starved [24]. PCr/
ATP ratios correlate with the clinical severity of heart
failure and are a prognostic indicator of mortality. Experi-
mental studies suggest that these changes can result in
increased free ADP levels when the failing heart is stressed.
Increased free ADP levels, in turn, result in a reduction in
the available free energy of ATP hydrolysis, which may
directly contribute to contractile dysfunction. MRS can also
be used to identify and assess viable myocardium, although
measurement of absolute concentrations of high-energy
phosphates is required to assess the extent of viable tissue
loss, as necrosis and scar formation result in reduced levels
of phosphocreatine and ATP. Accordingly, in patients with
fixed 201-Thallium defects, the absolute content of myo-
cardial ATP as measured by 31P-MRS is reduced, whereas
it remains constant in those with viable myocardium [27].
MRS is generally more suitable for the evaluation of
myocardium with a spatially homogeneous pathology, such
as dilated cardiomyopathy. However, application of a
technique called spectral localization with optimum point
spread function (SLOOP) allows for the examination of
voxel of any shape, in contrast to conventional rectangular
voxels. Matching voxel shape to the curvature of the heart
helps to increase the signal to noise ratios and avoid
contamination from myocardial tissue outside the region of
interest and from skeletal muscle and blood. The latter is
particularly relevant for 31P MRS, since blood gives rise to
a signal for 2,3-diphosphoglycerate, which resonates at a
frequency close to Pi, making Pi quantification as well as
determination of the intracellular pH difficult. The applica-
tion of SLOOP allows for the measurements of absolute
concentrations of PCr and ATP. Using (31)P saturation
transfer MRS techniques it is possible to measure flux
through the CK reaction in the intact heart [24]. The
application of this technique has proven that flux is reduced
in failing myocardium in both experimental models and in
patients. The study of transgenic animal models by MRS
has also been performed and has led to further insights into
the role of energy metabolism in heart failure, suggesting
that an intact creatine/CK system is critical for situations of
cardiac stress [25]. Nevertheless, MRS is currently used
primarily as a research tool, since low spatial and temporal
resolution and low reproducibility preclude its diagnostic
use in clinical practice. Future technical developments and
use of higher magnetic field strengths, such as the 7 Tesla
systems, will enable improvements in resolution and
reproducibility that may take cardiac MRS into the clinical
realm [28]. It is hoped that enrichment studies using C-13
labeled precursors, which have been performed in animals,
may also be performed in humans to measure parameters
such as the metabolic rate of glucose in vivo.
Single Photon Emission Tomography
Single photon emission tomography has been extensively
used in clinical practice for evaluation of relative myocar-
dial perfusion and function. Therefore, SPECT cameras are
widely available in clinical and research settings. Unlike
PET radioisotopes, many SPECT radioisotopes decay at
different energies and, therefore, several different biological
processes can theoretically be imaged simultaneously with
SPECT at different energy windows. Furthermore, unlike
PET, which utilizes coincidence circuitry to detect two anti-
parallel photons, SPECT cameras are designed to detect
single photons. Only photons traveling parallel to the
detector crystal are detected and all other photons are
discarded by a collimator. Since SPECT cameras typically
do not contain a transmission source, SPECT is typically
able to identify only relative changes in concentration of the
radiopharmaceutical rather than absolute concentrations. In
this respect, the role of SPECT in the quantitation of
myocardial metabolism is limited. Table 2 compares the
advantages and disadvantages of PET, MRS, and SPECT
for quantification of myocardial metabolism. Despite these
limitations, Okizaki et al. were able to perform a compart-
ment model analysis of myocardial fatty acid metabolism in
patients with hypertrophic cardiomyopathy using SPECT
with 123I-beta-methyl-iodophenylpentadecanoic acid
(123I-BMIPP), a fatty acid analog and 99mTc-tetrofosmin
perfusion radiotracer [29]. Using the myocardial and blood
pool time-activity curves, 123I-BMIPP pharmacokinetics
were analyzed through a two-compartment model. k1 and k2
were defined as influx and outflux rate constants between
blood and myocardial reversible component, and k3 as the
specific uptake rate constant between myocardial reversible
and irreversible compartments. The authors concluded that
k3 might be a sensitive predictor for early detection of
hypertrophic cardiomyopathy, and k1/k2 could be a useful
390 J. of Cardiovasc. Trans. Res. (2010) 3:384–396index to evaluate its progression. Yazaki et al. performed a
study to determine the clinical and prognostic value of
identifying metabolic abnormalities of myocardial fatty acid
metabolism in idiopathic dilated cardiomyopathy using
123I-BMIPP in 32 patients [30]. They found that the extent
of the abnormality of myocardial fatty acid metabolism in
idiopathic dilated cardiomyopathy reflected the severity of
hemodynamic deterioration and histopathological changes.
However, it should be noted that the actual kinetics of 123I-
BMIPP are complex and have not been validated in heart
failure. Another disadvantage of SPECT is that there are
currently no available SPECT radiotracers to measure
myocardial glucose metabolism, although a SPECT camera
may theoretically be fitted with an appropriate collimator to
image18F-FDG.
Fick Method and Metabolic Profiling
The Fick method was first devised as a technique for
measuring cardiac output; however, its underlying principles
may be also applied to measure uptake and secretion rates of
substrates by the myocardium. Myocardial substrate uptake
rates are calculated by taking the product of myocardial
perfusion and the difference of substrate concentrations in
arterial blood and venous blood from the coronary sinus.
Myocardial perfusion can be obtained with the 133-Xenon
washout technique, which utilizes a scintigraphic detector,or
approximated via the thermodilution technique [31]. Unlike
PET, SPECT, and MRS, the Fick method is an invasive
procedure, but can still be carried out in human subjects in
vivo. While imaging technologies are able to quantify only
several metabolic parameters in the myocardium at a time,
the Fick method can provide a more complete evaluation of
metabolism. Wisneski et al. used the Fick method to
demonstrate that the circulating level of free fatty acids
plays a major role in determining the amount of glucose
extracted and oxidized by the normal human myocardium
[32]. In this study coronary sinus and arterial catheters were
placed in 23 healthy male volunteers and 6-14C glucose
and U-13C lactate were infused. Simultaneous blood
samples were obtained for chemical analyses of glucose,
lactate, and free fatty acids and for the isotopic analyses of
glucose and lactate.
The Fick has been used to quantify a large number
metabolic processes in the myocardium at a time,
including fluxes of oxygen, glucose, fatty acids, lactate,
pyruvate, beta-hydroxybutyrate, and amino acids such as
glutamate, alanine, and aspartate. Since these data sets
are more extensive than those obtained with imaging
methods, they may be more amendable to mathematical
models such as constraint-based metabolic network
modeling. Vanky et al. [31] applied the Fick method to
study myocardial uptake of oxygen and energy substrates
before and after valve replacement for aortic stenosis. In
this study, preoperative and postoperative metabolic
adaptation with substantial uptake of glutamate, previously
claimed to be due to chronic or repetitive ischemia, was
demonstrated.
Recent advances in the application of the Fick Method
include high-throughput approaches such as mass spec-
trometry to perform metabolic profiling of the myocardial
substrate metabolism in vivo. A study by Turer et al.
[33], for instance, applied a mass spectrometry-based
platform to profile 63 intermediary metabolites in serial
pairedperipheral arterial and coronary sinus blood effluents
obtained from 37 patients undergoing cardiac surgery,
stratified by presence of coronary artery disease or left
ventricular dysfunction. The authors found that the dys-
functional ventricle is characterized by global suppression
of metabolic fuel uptake and limited myocardial metabolic
reserve and flexibility after global ischemia/reperfusion
stress in the setting of cardiac surgery. Altered metabolic
profiles after ischemia/reperfusion were associated with
postoperative hemodynamic course, suggesting a role for
perioperative metabolic monitoring and targeted optimiza-
tion in cardiac surgical patients. Nevertheless, one of the
disadvantages of the Fick method is that it only provides
quantitative metabolic flux measurements of the entire
Table 2 Advantages and disadvantages of PET, MRS, and SPECT in evaluation of myocardial metabolism
Advantages Disadvantages
PET Quantitative metabolic and blood flow measurements; high
sensitivity; radiotracers as natural substrates and chemical
analogs; many metabolic radiotracers available
Cyclotron needed on site due to short half lives; only one process
can be evaluated at a time; difficulty with separating reaction
steps in a pathway
MRS Simultaneous measurements of multiple metabolic pathways and
function; ease in performing serial measurements, no ionizing
radiation; higher field strength in small animal imaging
Poor sensitivity (millimolar); low signal to noise ratio; intravoxel
signal contamination; long acquisition times; measurement
limited to anterior wall in humans
SPECT High sensitivity; widely available; long half lives facilitate
radiopharmaceutical delivery; simultaneous imaging of two
radiopharmaceuticals with different energies; ECG gating for
myocardial function
Inability to quantify processes with lack of attenuation correction;
poor temporal and spatial resolution; few radiopharmaceuticals
available for evaluation of metabolism
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provide information on regional myocardial metabolism
and evaluate its heterogeneity.
Modeling of Myocardial Metabolism
Constraint-Based Metabolic Network Model
Constraint-based modeling developed out of the availability
of fully sequenced genomes in the mid-1990s, when it
became possible to compile complete parts lists initially for
bacterial organisms [34] and eventually humans [35, 36].
The generation of these large volumes of data created the
need to organize this vast biological information. Hence, a
systems approach was required that could be used to
construct genome or organelle-scale models using large,
yet still incomplete data sets. This information, coupled to
the rich biochemistry literature, notable for fundamental
work elucidating biochemical mechanisms of action and
catalysis, enabled the definition of metabolic stoichiometric
networks and the subsequent ability to formulate the
networks in terms of a linear programming problem [37].
The underlying principle of this modeling approach is to
balance the inputs and outputs of a system at a non-
equilibrium steady state (Fig. 4). This approach has many
benefits, including the flexibility for incorporating and
integrating various data types and incomplete data sets. A
challenge resulting from these benefits is the fact that there
exist many points that satisfy the solution space. This
problem can be alleviated in part through the choice of an
appropriate metabolic objective function, such as biomass
production in bacteria grown in the laboratory or ATP
synthesis in the cardiomyocyte. Evaluation of existing
objective functions and investigation of new and alternative
functions is an active area of development in this field [38].
Additionally, constraint-based modeling problems can be
carried out without specifying an objective function
through randomly sampling the feasible solution space,
thus calculating flux probability distributions for every
reaction within the network [39]. There are numerous other
methods that can be applied to the network and newer ones
continue to be developed as part of the constraint-based
modeling approach [40].
vin vout
vin –v out = 0
succinyl-CoA
Fig. 4 Human cardiomyocyte mitochondria; a bird’s eye view of the
cardiomyocyte mitochondria metabolic network. Each node represents
a chemical species and each line represents an enzymatic (or
spontaneous) reaction converting substrates into products. Elementally
charge and mass balanced equations are specified for every reaction in
the network. Application of steady-state conditions amounts to
balancing each element constituent of the chemical species
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attempt to be comprehensive, but are known to be incom-
plete, is a strong advantage of constraint-based network
modeling [41]. Proteomic data has, for example, been used
in conjunction with biochemical data in the literature (the
bibliome) to generate a reconstruction of the human
cardiomyocyte. Initial analyses using data from the literature
enabled the postulation of alternate mechanisms for regula-
tion of key enzyme fluxes, such as pyruvate dehydrogenase
in diabetic conditions [42]. The use of gene–protein–
reaction relationships [43] in genome or organelle-scale
models enables mapping of various high-throughput data
on networks for analysis. This can be used to analyze
systemic consequences of genetic mutations and genotype–
phenotype relationships. For example, the analysis of
multiple causal single nucleotide polymorphisms within
the network can be assessed to evaluate the influence of
genetic mutations on different reactions within the cardio-
myocyte mitochondria, and to subsequently carry out
correlations among the different reactions to find a smaller,
unique set of predicted phenotypes [44]. MRS data, which
is becoming increasing available, also has applications for
analysis of genome scale models. Studies have recently
been carried out using 1H NMR spectroscopy data
investigating systemic effects of hypoxia in Drosophila
[45]. The use of 13C-isotopomer-labeled metabolic sub-
strates, such as glucose and long-chain fatty acids, can be
used to trace fluxes of molecules within network and to
analyze them under mass conservation constraints [46].
Analysis of isotopomer uptake experiments from perfused
mouse hearts via an in silico cardiomyocyte model enabled
the identification of fluxes through various pathways. A
study of the mouse cardiomyocyte using 13C-labeled glucose
andfattyacidssuggestedasmallroleforanapleuroticfluxes,a
predominant uptake of glucose over the 18 carbon fatty acids,
but approximately 1/2 of the contribution to ATP production
originating from glucose when compared to oleic acid [47].
While the development of constraint-based genome or cell
scale models is still in relatively early stages, developments
made to date, particularly in bacterial organisms, show great
promise and potential in aiding the study of complex multi-
cellular systems. Imaging technologies such as MRS and
PET, coupled with blood flow measurements, may aid in the
determination of multiple small metabolite input/output
fluxes for metabolic network models. These measured
parameters can serve as constraints on the networks and
enable a more comprehensive systems analysis, with clinical
applications spanning from classification and diagnosis to
potentially serving as prognostic measures, provided that








Fig. 5 The creatine kinase reaction allows exchange between creatine phosphate and ATP for energy storage via the high-energy phosphate bond
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From a metabolic perspective, cardiac function is to pump
blood to the pulmonary and systemic circulation and to
perfuse all tissues, thus providing oxygen and substrates
and removing waste products. High-energy phosphate
bonds serve as the cells’ energy currency, which is stored
in the adenosine phosphate and creatine phosphate pools in
heart tissue. The chemical reaction depicted in Fig. 5
summarizes core energy transfer in cardiac tissue, coupled
to the ATP hydrolysis reaction. The significance and
potential practical applications of 31P MRS have long been
recognized as a means for carrying out measurements on
intact tissue [48]. Under the assumption of constant total
creatine during the experimental course, the ADP concen-
tration can be calculated, and other phosphate-bound
metabolites can be identified and quantified from the
MRS spectra. This enables assessment of in vivo energy
states of the cardiomyocyte and comparisons can be carried
out under different experimental conditions investigating
the effects of hypoxia and/or ischemia. Some initial
observations, such as the constancy of ATP, inorganic
phosphate, and creatine phosphate levels as well as a two-
to threefold increase in oxygen demand [49] accompanied
by changes in ratios of the metabolites (e.g., ATP/ADP
ratio) with ischemia all highlight that complex control
mechanisms are involved. These observations stimulated
the development of more complex models [50–52] for
exploring mechanisms of regulation of metabolism in
normal as well as pathophysiological conditions. Recent
studies suggest that inorganic phosphate may be a critical
factor in feedback and prediction of cardiac capacity under
normal and ischemic conditions [53]. More recently the size
of the adenine nucleotide pool has been shown to be an
important parameter for characterizing left ventricular
hypertrophic heart failure in canines [54]. This finding is
consistent with earlier statements that key metabolite
moiety pool sizes are important in determining cellular
function [55]. Interestingly, the pool size of nucleotide
precursors has been identified as an important indicator of
function in other tissues as well [56]. Developments such as
these may provide investigators with potential biomarkers
for qualitative or even quantitative metabolic assessment of
cardiac status in the clinical setting.
Integration of Data and Organization of Efforts
Integrationisthe central theme ofSystems Biology.However,
giventhe complexityofbiologicalsystems,“integration”may
refer to several different concepts, such as the integration of
data across spatial hierarchies, temporal hierarchies, or
various biological processes. Developments in the integration
of metabolism with cardiac function include incorporation of
excitation–contraction coupling, ATP generation [57], and
molecular contraction mechanisms [58]. As more and more
complex data sets became available and a wide range of
models describing biological functions (from excitation–
contraction coupling to metabolism to mechanical contrac-
tion) were developed, it was recognized that there would be
a need to organize these efforts. Anticipating these develop-
ments, a number of organizations and initiatives have been
underway to meet these new developments and to maximize
the utility of these efforts [59–61]. The Human Physiome
Project, launched by the International Union of Physiological
Sciences in 1997, was one of the earlier efforts recognizing
the importance of incorporating data obtained with imaging
modalities, such as PET and MRS, in future applications of
myocardial metabolism modeling. Aside from the technical
challenges of experimental tools and methods to develop
these projects, there is a concurrent need to maintain a set of
standards. This has been recognized as a challenge in
mathematical modeling fields [62] with regards to criteria
for developing and assessing model quality, as well as
availability of formats that are accessible to the scientific
community. Fortunately, these issues have been recognized
and are addressed in the Human Physiome Project [63].
While the challenges are notable, the prospects of even small
advances warrant further efforts in the integration of in vivo
imaging data and mathematical models of myocardial
metabolism.
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